Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer

BJU International

Volumn 104, Issue 11, 2009, Pages 1580-1584

  Kirby, Roger S ^a   Fitzpatrick, John M ^c   Clarke, Noel ^b  

^a Prostate Centre   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MATER PRIVATE HOSPITAL   (Ireland)

Author keywords

Abarelix; Degarelix; GnRH antagonists; Hormone therapy; LHRH agonists; Prostate cancer

Indexed keywords

ABARELIX; ANTIANDROGEN; BICALUTAMIDE; BOLDENONE; BUSERELIN; CETRORELIX; DEGARELIX; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ANDROGEN BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTINUOUS INFUSION; DESENSITIZATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LUTEINIZING HORMONE BLOOD LEVEL; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PRURITUS; SHORT SURVEY; SPINAL CORD COMPRESSION; SYNCOPE; TESTOSTERONE BLOOD LEVEL; URTICARIA;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; EPIDEMIOLOGIC METHODS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 70449334504     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08924.x     Document Type: Short Survey

References (28)

1. Cancer Research UK. Available at: http://info.cancerresearchuk.org/ cancerstats/types/prostate/
2. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55 : 10 30
3. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002 38 : 99 166 (Pubitemid 34031832)
4. Heidenreich H, Aus G, Abbou CC et al. Guidelines on prostate cancer. European Association of Urology, 2007. Available at: http://www.uroweb.org/ fileadmin/tx-eauguidelines/Prostate%20Cancer.pdf
5. Sasagawa I, Kubota Y, Nakada T et al. Influence of LHRH analogues on serum levels of PAP and PSA in patients with metastatic carcinoma of the prostate. Int J Urol Nephrol 1998 30 : 745 753
6. Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000 56 : 1021 1024
7. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000 132 : 566 577
8. Heidenreich A, Aus G, Abbou CC et al. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80
9. Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001 58 (Suppl. 1 5 9
10. Van Poppell H, Nilsson S. Testosterone surge: rationale for GnRH hormone blockers. Urology 2008 71 : 1001 1006
11. Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: Results from two multicentre randomized trials at a median follow-up of 4 years. Urology 1998 51 : 389 396
12. Tyrrell CJ, Iversen P, Tammela T et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006 98 : 563 572
13. Molineaux CJ, Sluss PM, Bree MP et al. Suppression of plasma gonadotropins by abarelix: a potent new LHRH antagonist. Mol Urol 1998 2 : 265 271
14. Streda R, Mardesic T, Sobotka V, Tosner J. Long GnRH agonist vs. GnRH antagonist protocol in randomized controlled trial in unselected patients - hormonal and cycle characteristics - pilot study. Ceska Gynekol 2009 74 : 75 80
15. Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008 54 : 170 177
16. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 2008 102 : 1531 1538
17. Tomera K, Gleason D, Gittelman M et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001 165 : 1585 1589
18. Koch M, Steidle C, Brosman S et al. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 2003 62 : 877 882
19. McLeod D, Zinner N, Tomera K et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001 58 : 756 761
20. Teillac P, Debruyne FMJ, Schulman CC, Jonas U, Selvaggi FP, for the ABACAS 1 Study Group. ABACAS 1: a comparison of the eficacay and safety of abarelix versus goserlein plus bicalutamide in patients with advanced or metastatic prostate cancer. A one year randomized open-label multicentre, Phase III trial. Eur Urol 2001 39 (Suppl. 5 78
21. Trachtenberg J, Gittleman M, Steidle C et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002 167 : 1670 1674
22. Wong SL, Lau DT, Baughman SA, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 2003 73 : 304 311
23. Debruyne F. GnRH antagonists in the management of prostate cancer. Rev Urol 2004 6 (Suppl. 7 S25 32
24. Praecis Pharmaceuticals. Abarelix for Injectable Suspension. Prescribing Information. Cambridge, MA : Praecis Pharmaceuticals Inc, 2004
25. Praecis Pharmaceuticals. Data on file. Praecis Pharmaceuticals Inc, 2009
26. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002 301 : 95 102
27. Kreis W, Ahmann FR, Jordan VC, de Haan H, Scott M. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation. Br J Urol 1988 62 : 352 354
28. Waxman J, Man A, Hendry WF et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res) 1985 291 : 1387 1388